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Sanofi Pasteur, a vaccine manufacturer that does not make an HPV vaccine

•

Universities, including UCLA and University of Rochester

•

Not-for-profit organizations, including AAP and its chapters, Immunization
Action Coalition, and Immunize Kansas Coalition

BY THE END OF THE WEBINAR,
YOU SHOULD BE ABLE TO:
1. Explain why HPV vaccine is important enough to be
routinely recommended for young people
(i.e., HPV cancer prevention).

2. Give an HPV vaccination recommendation that is
effective and succinct using the same way, same
day approach to the introduction of HPV vaccine.
3. Answer the most frequently asked questions about
HPV vaccine accurately and succinctly.

1: Why HPV vaccine
is important enough to be
routinely recommended
for young people

NEW HPV-ASSOCIATED

CANCER CASES EACH YEAR

BASED ON DATA FROM

Cervix

Oropharynx

Source: https://www.cdc.gov/cancer/uscs/about/data-briefs/no10-hpv-assoccancers-UnitedStates-2012-2016.htm

2012-2016

CANCERS CAUSED BY THE 9 VACCINE TYPES OF HPV
PER YEAR, U.S., 2012–2016
Cancer site

% caused by 9
vaccine HPV types

# probably caused by 9 vaccine types-HPV
Female

Male

Both Sexes

Cervix

81%

9,700

0

9,700

Vagina

73%

600

0

600

Vulva

63%

2,500

0

2,500

Penis

57%

0

700

700

Anus*

88%

4,100

1,900

6,000

Oropharynx

66%

2,100

10,500

12,600

19,000

13,100

32,100

TOTAL
*Includes anal and rectal squamous cell carcinomas

Source: https://www.cdc.gov/mmwr/volumes/68/wr/mm6833a3.htm

OUR UNDERSTANDING OF HPVASSOCIATED CANCERS IS EVOLVING
Prostate cancer -causal role for HPVs is highly likely

Source: Lawson and Glenn
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359253/

•

•
•

HPV-associated cancers were defined as cancers at specific anatomic sites with
specific cellular types in which HPV DNA frequently is found.
All cancers were confirmed histologically.
Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard Population

Source: https://gis.cdc.gov/Cancer/USCS/DataViz.html
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CREATE IMMUNIZATION CHAMPIONS
Be sure everyone in the office understands the mission
• Human stories usually
influence people more
than statistics

• To understand the human
stories behind HPV, listen
to survivors
o Shot By Shot.org
o ACS HPV survivor stories

OROPHARYNGEAL CANCER SURVIVOR

American Cancer Society
HPV Survivor – Frank Summers
https://www.youtube.com/watch?v=D2Ki-gC7OhM

A VIRUS THAT CAUSES CANCER…
EFFECTIVE, SAFE, LONG-LASTING
VACCINE… SO EVERYONE’S KNOCKING
DOWN THE DOOR
TO GET THEIR CHILD PROTECTED,

RIGHT?

Minnesota
73.8%
Wisconsin
72.2%
North Dakota 88.8%
https://app.powerbigov.us/view?r=eyJrIjoiMDY2OWM2ZmEtYjE2Yy00MTM5LWI
5ZGUtODU5MGE1NWMxM2M4IiwidCI6IjljZTcwODY5LTYwZGItNDRmZC1hYmU4L
WQyNzY3MDc3ZmM4ZiJ9&pageName=ReportSection561f78b2709c4087d370

Age 13-17
Minnesota 73.8%
Wisconsin 72.2%
N Dakota
88.8%

Ann Long can
get specific data
for you
by clinic and/or
by provider

Allina Health measures both vaccines by age 13
Overall
Male
Female

40.6% (986/2430)
40.2% 479/1193
41% 507/1237

Regions
West Metro
North Metro
East Metro
East
Northwest
Southwest
North

55.9%
53%
50%
35.4%
35.1%
34.8%
34.6%

2: Identify patients for whom
HPV vaccine is recommended

ROUTINE ON-TIME VACCINATION
• Ages 9 through 14
• 2 doses (unless immunocompromised relative to HPV)
• Separated by 6-12 months (minimum 5 months)

Source: https://www.cdc.gov/hpv/hcp/schedules-recommendations.html

Source: https://www.cdc.gov/hpv/hcp/schedules-recommendations.html

HPV VACCINE RECOMMENDATIONSROUTINE

• Routine On-time Vaccination

o Ages 9 through 14
o 2 doses (unless immunocompromised relative to HPV)
o Separated by 6-12 months (minimum 5 months)

•

Routine Delayed Vaccination
o Ages 15 through 26
o 3 doses
o Doses 1 & 2 separated by 1-2 months (min 4 wks)
Doses 1 & 3 separated by 6 months (min 5 mos)
Doses 2 & 3 separated by at least 12 weeks
o If started at age 26, complete series when 27

If the series is interrupted, it does not need to be restarted.

HPV VACCINE RECOMMENDATIONSSCDM
• For adult ages 27-45 years ACIP has voted to recommend
“shared clinical decision making”

• 3 doses, same schedule as young adults
• Benefit? 80% of HPV infections that go on to cause cancer
are acquired before age 26. Estimated # of HPV-related cases
of cancer that can be prevented every year by vaccination:

o Vaccinated from 9 to 26 years of age: 25,000
o Vaccinated from 27 to 45 year of age:
193

• Risks? Very low

3: Explain why HPV vaccine is
more likely to protect women
from fertility issues
than to cause them

HPV VACCINATION

ELIMINATES

HPV INFECTION

AND THE DOWNSTREAM CONSEQUENCES

HPV vaccination

Genital HPV infection
79 million

Source: Schiffman M et al., 2013

Cervical
Pre-cancer
330,000

Cervical Cancer
12,000

CERVICAL CANCER DURING
CHILD-BEARING YEARS
38% of cervical cancers occur in women between the
ages of 20 & 44 years.

Source: http://seer.cancer.gov/statfacts/html/cervix.html

WITHOUT VACCINATION, ANNUAL BURDEN OF
GENITAL HPV-ASSOCIATED DISEASE IN U.S.
FEMALES
4,000 cervical cancer deaths
10,846 new cases of cervical cancer

330,000 new cases of HSIL: CIN2/3
(high grade cervical intraepithelial neoplasia)

350,000 new cases of genital warts

1.4 million new cases of LSIL: CIN1(low
grade cervical intraepithelial neoplasia)

Source: American Cancer Society. 2008; Schiffman, Mark, and Philip E. Castle.; Koshiol Sex
Transm Dis. 2004; Insinga, Ralph P., Erik J. Dasbach, and Elamin H. Elbasha, 2005
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EVEN PRE-CANCEROUS LESIONS HAVE
IMPLICATIONS FOR A WOMAN AND HER
OFFSPRING
New cases of cervical dysplasia each year in the US:
– 1.4 million low grade
– 330,000 high grade

Loop electrosurgical excision procedure (LEEP) or a cold-knife
cone biopsy

LEEP AND CONE BIOPSY
▪ May be used to treat moderate to severe types of
abnormal cell changes (CIN II or CIN III) or even very
early stage cervical cancer
▪ Subsequent pregnancies are at risk of
o Perinatal mortality
o Preterm delivery
o Low birth weight
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VACCINE TYPE-HPV INFECTIONS,
US FEMALES

18
16
14

61% decline

71% decline

Pre-vaccine era 2003-2006

12

Early vaccine era 2007-2010

10

Later vaccine era 2011-2014

8
6
4
2
0
14-19

20-24

Study also found vaccine type-HPV decreased 89% for vaccinated girls and
34% for unvaccinated girls: herd immunity
Source: Oliver, et al. JID 2017
https://academic.oup.com/jid/article/216/5/594/3892427

COCHRANE REVIEW:
HPV VACCINE EFFECTIVENESS AGAINST
CERVICAL PRECANCER
• Among previously un-infected women # of women who developed cervical precancer
o Placebo: 164 per 10,000 women
o HPV vaccine: 2 per 10,000 women who got the vaccine

• Regardless of infection status at outset HPV vaccines reduced the risk of cervical precancer
o Associated with HPV16/18:from 341 to 157/10 K
o Any precancer lesions:
from 559 to 391/10 K
Source: https://www.cochrane.org/news/does-hpv-vaccination-prevent-developmentcervical-cancer-are-there-harms-associated-being

October 2020

“We found that the
risk of cervical cancer
among participants
who had initiated
vaccination before
the age of 17 years
was 88% lower than
among those who
had never been
vaccinated.”

4: Recommend this vaccine the
same way you recommend
other vaccines

HOW EFFECTIVELY ARE WE
COMMUNICATING?
Our recommendations
matter to parents!
MN Dept of Health’s
“Just another shot: Reframing the HPV
vaccine”
https://www.youtube.com/watch?v=v
FHjK5L0t-Y&feature=emb_title
Source: https://www.health.state.mn.us/people/immunize/hcp/hpvvideos.html

OPTIONAL VERSUS HIGH QUALITY
• Optional approach: “Have you thought about what
shots you’d like to get today?”
o Unintentionally implies shot is not important or few get it
o 20-30% vaccination rate in studies of child & teen vaccines

• High quality: “Today we have some shots for you.”
o Implies shot is important and most people get it
o 70-90% vaccination rate in studies of child & teen vaccines

MAKE AN EFFECTIVE RECOMMENDATION
• Same day: Group all the adolescent vaccines,
recommend HPV vaccination the same way you
recommend Tdap & meningococcal vaccines
• Same day: Recommend HPV vaccine today,
i.e., the same day you recommend Tdap &
meningococcal vaccines
• Put HPV in the middle between Tdap &
meningococcal vaccines

PUTTING HIGH QUALITY RECOMMENDATIONS
INTO PRACTICE: SAME WAY, SAME DAY
“Your child needs 3 vaccines today- Tdap, HPV and
meningococcal”
If starting before age 11, you can say:
“Today, your child needs the HPV vaccine to protect
him against cancers and other diseases caused by
HPV.”

EVERY PART OF YOUR PRACTICE
INFLUENCES PARENTS’ PERCEPTIONS

THE OPENER BY THE NURSE/MA
• Encourage convenient same-day vaccination
“Today, Pat should have 3 vaccines to protect him
from meningitis, HPV cancers, and pertussis. Do you
have any questions for me?”
• If a parents hesitates, the MA/nurse should say
“I’m sure the doctor will want to talk with you about
your concerns.”

5: Answering parents’ questions

Source: https://www.cdc.gov/hpv/hcp/for-hcp-tipsheet-hpv.pdf

TIP #1: REFLECT, ASK PERMISSION
Reflect back what the parent said to be
sure he/she understands (empathy) and
asks permission to share their own
perspective.
“You feel that she’s too young for the
HPV vaccine because HPV is
transmitted by sexual activity.
I can see what you’re saying.
I’ve thought a lot about this.
Is it okay if I tell you how I’ve come to
think about this?”

TIP #2: PROVIDE INFO TO CHANGE
PARENT’S PERSPECTIVE
“I used to think of this vaccine as something to prevent
a sexually transmitted disease, but realized it’s really
about preventing cancer.”
“We recommend it at this age because younger kids
have a better immune response. That’s why they need
only 2 doses instead of 3.”
This avoids arguing. You haven’t contradicted the parent’s point.

TIP #3: AVOID COUNTERING EMOTION
WITH DATA

What NOT to say: “Well data shows that many
adolescents will be having sex by middle school, and if
you’re worried about her having sex, studies have
shown that it won’t increase the likelihood of her
having sex.”

Statistics do not work in an
emotional argument.

TIP #4:
IF A PARENT DECLINES THE HPV VACCINE
• Declination is not final
o Many parents who decline, will vaccinate later
o The conversation should be revisited

•
•
•
•

Offer reading material
Don’t over-remember this
Relax. You’ve done your best for this child.
Waiting to vaccinate is the risky choice, so some
pediatricians ask parent to sign a Declination Form

HOW DO YOU HANDLE OBJECTIONS
BASED ON RELIGION?

EXAMPLE OF EFFECTIVE PROVIDER
COMMUNICATION
Minnesota Department of Health’s
“HPV vaccine: It’s effective”
https://www.youtube.com/watch?time_continue
=2&v=huyn7M8VmqI&feature=emb_title
Or https://www.health.state.mn.us/people/immunize/hcp/hpvvideos.html

GREAT JOB!
• He seized the moment
• He did not “profile”
• He bundled the recommendation

• He asked for mom’s question
• He answered mom’s question accurately and calmly
• When mom asked the 2nd question:
“some people…”, he stayed positive

• He cared (“I’d feel better”)

6: Bring adolescents back to
your office

Allina’s strategies to bring patients in
• Schedule 2nd vaccine prior to patient leaving
clinic
• Health Maintenance system reminder 1
month before 2nd vaccine is due
• Reporting workbench for clinical staff to
contact patients overdue for vaccine
• Coming soon – System email reminder when
patient is 1 month overdue for 2nd vaccine

Wrap up

Annual Incidence (per 100,000)

INCIDENCE OF DISEASES PREVENTABLE BY 3
ADOLESCENT VACCINES, US
8
7
6
5
4
3
2
1
0

7.2
5.6

0.12

0.04

Meningococcal
Disease (all
serogroups)

Meningococcal
Disease
Serogroup B

Pertussis

4.8

Oropharyngeal Cervical Cancer
Cancer (HPV- (HPV-associated)
associated)

Sources: Meningococcal Disease, CDC, 2016, https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report.pdf; Pertussis, CDC, 2016,
https://www.cdc.gov/pertussis/downloads/pertuss-surv-report-2016.pdf; HPV, CDC, 2011-2015, https://www.cdc.gov/cancer/hpv/pdf/USCS-DataBriefNo4-August2018-508.pdf; www.cdc.gov/mmwr/volumes/67/wr/mm6733a2.htm#T1_down

AAP’S EQIPP: IMMUNIZATIONS - STRATEGIES FOR SUCCESS
HTTPS://SHOP.AAP.ORG/EQIPP-IMMUNIZATIONS-STRATEGIES-FOR-SUCCESS/

• Free to members
• Identify immunization rates in your practice, uncover
barriers to immunization delivery systems, and
provide techniques to overcome those barriers
through clear aims that reflect expert principles and
proven quality improvement methods and tools
• Choice of tracks
– 19-23 months old
– adolescent

WRAP UP
Patients for whom HPV vaccination is recommended

HPV vaccination supports healthy pregnancy

Presumptive recommendations for vaccination work

Plan to bring adolescents to your office for vaccination
Evaluate how results of HPV vaccination QI projects
could be applied in your office

